Literature DB >> 12409354

Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples.

Dana DeVange Panteleeff1, Sandra Emery, Barbra A Richardson, Christine Rousseau, Sarah Benki, Sharon Bodrug, Joan K Kreiss, Julie Overbaugh.   

Abstract

Human immunodeficiency type 1 (HIV-1) continues to spread at an alarming rate. The virus may be transmitted through blood, genital secretions, and breast milk, and higher levels of systemic virus in the index case, as measured by plasma RNA viral load, have been shown to correlate with increased risk of transmitting HIV-1 both vertically and sexually. Less is known about the correlation between transmission and HIV-1 levels in breast milk or genital secretions, in part because reliable quantitative assays to detect HIV-1 in these fluids are not available. Here we show that the Gen-Probe HIV-1 viral load assay can be used to accurately quantify viral load in expressed breast milk and in cervical and vaginal samples collected on swabs. Virus could be quantified from breast milk and swab samples spiked with known amounts of virus, including HIV-1 subtypes A, C, and D. As few as 10 copies of HIV-1 RNA could be detected above background threshold levels in > or =77% of assays performed with spiked breast milk supernatants and mock swabs. In genital swab samples from HIV-1-infected women, similar levels of HIV-1 RNA were consistently detected in duplicate swabs taken from the same woman on the same clinic visit, suggesting that the RNA values from a single swab sample can be used to measure genital viral load.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409354      PMCID: PMC139629          DOI: 10.1128/JCM.40.11.3929-3937.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial.

Authors:  R Nduati; G John; D Mbori-Ngacha; B Richardson; J Overbaugh; A Mwatha; J Ndinya-Achola; J Bwayo; F E Onyango; J Hughes; J Kreiss
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

2.  The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1.

Authors:  C C Wang; R S McClelland; M Reilly; J Overbaugh; S R Emery; K Mandaliya; B Chohan; J Ndinya-Achola; J Bwayo; J K Kreiss
Journal:  J Infect Dis       Date:  2001-02-28       Impact factor: 5.226

3.  Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

Authors:  S Emery; S Bodrug; B A Richardson; C Giachetti; M A Bott; D Panteleeff; L L Jagodzinski; N L Michael; R Nduati; J Bwayo; J K Kreiss; J Overbaugh
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  Comparison of two amplification technologies for detection and quantitation of human immunodeficiency virus type 1 RNA in the female genital tract. Division of AIDS Treatment Research Initiative 009 Study Team.

Authors:  J Bremer; M Nowicki; S Beckner; D Brambilla; M Cronin; S Herman; A Kovacs; P Reichelderfer
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

5.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

6.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Authors:  P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

7.  Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections.

Authors:  G C John; R W Nduati; D A Mbori-Ngacha; B A Richardson; D Panteleeff; A Mwatha; J Overbaugh; J Bwayo; J O Ndinya-Achola; J K Kreiss
Journal:  J Infect Dis       Date:  2000-12-15       Impact factor: 5.226

8.  Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Authors:  R Chuachoowong; N Shaffer; W Siriwasin; P Chaisilwattana; N L Young; P A Mock; S Chearskul; N Waranawat; T Chaowanachan; J Karon; R J Simonds; T D Mastro
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

10.  Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.

Authors:  J W Mellors; L A Kingsley; C R Rinaldo; J A Todd; B S Hoo; R P Kokka; P Gupta
Journal:  Ann Intern Med       Date:  1995-04-15       Impact factor: 25.391

View more
  32 in total

1.  Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment.

Authors:  Susan M Graham; Linnet Masese; Ruth Gitau; Zahra Jalalian-Lechak; Barbra A Richardson; Norbert Peshu; Kishor Mandaliya; James N Kiarie; Walter Jaoko; Jeckoniah Ndinya-Achola; Julie Overbaugh; R Scott McClelland
Journal:  J Infect Dis       Date:  2010-10-05       Impact factor: 5.226

2.  Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.

Authors:  Alison L Drake; Alison C Roxby; Francisca Ongecha-Owuor; James Kiarie; Grace John-Stewart; Anna Wald; Barbra A Richardson; Jane Hitti; Julie Overbaugh; Sandra Emery; Carey Farquhar
Journal:  J Infect Dis       Date:  2011-12-06       Impact factor: 5.226

3.  Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments.

Authors:  Dorothy Mbori-Ngacha; Barbra A Richardson; Julie Overbaugh; Dana DeVange Panteleeff; Ruth Nduati; Matt Steele; Grace John-Stewart
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA.

Authors:  Susan M Graham; Zahra Jalalian-Lechak; Juma Shafi; Vrasha Chohan; Ruth W Deya; Walter Jaoko; Kishor N Mandaliya; Norbert M Peshu; Julie Overbaugh; R Scott McClelland
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

5.  Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation.

Authors:  Catherine A Blish; R Scott McClelland; Barbra A Richardson; Walter Jaoko; Kishorchandra Mandaliya; Jared M Baeten; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

6.  HIV-1-specific enzyme-linked immunosorbent spot assay responses in HIV-1-exposed uninfected partners in discordant relationships compared to those in low-risk controls.

Authors:  Brandon L Guthrie; Barbara Lohman-Payne; Amy Y Liu; Rose Bosire; Samuel Victor Nuvor; Robert Y Choi; Romel D Mackelprang; James N Kiarie; Stephen C De Rosa; Barbra A Richardson; Grace C John-Stewart; Carey Farquhar
Journal:  Clin Vaccine Immunol       Date:  2012-09-12

7.  Subtype C Is associated with increased vaginal shedding of HIV-1.

Authors:  Grace C John-Stewart; Ruth W Nduati; Christine M Rousseau; Dorothy A Mbori-Ngacha; Barbra A Richardson; Stephanie Rainwater; Dana D Panteleeff; Julie Overbaugh
Journal:  J Infect Dis       Date:  2005-06-23       Impact factor: 5.226

8.  Breast milk HIV-1 RNA levels and female sex are associated with HIV-1-specific CD8+ T-cell responses in HIV-1-exposed, uninfected infants in Kenya.

Authors:  Carey Farquhar; Barbara Lohman-Payne; Julie Overbaugh; Barbra A Richardson; Jennifer Mabuka; Rose Bosire; Dorothy Mbori-Ngacha; Grace John-Stewart
Journal:  J Infect Dis       Date:  2011-10-07       Impact factor: 5.226

9.  Depot Medroxyprogesterone Acetate Use Is Associated With Elevated Innate Immune Effector Molecules in Cervicovaginal Secretions of HIV-1-Uninfected Women.

Authors:  Brandon L Guthrie; Andrea Introini; Alison C Roxby; Robert Y Choi; Rose Bosire; Barbara Lohman-Payne; Taha Hirbod; Carey Farquhar; Kristina Broliden
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

10.  Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.

Authors:  Michael H Chung; James N Kiarie; Barbra A Richardson; Dara A Lehman; Julie Overbaugh; Grace C John-Stewart
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.